UNASSIGNED: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed.
UNASSIGNED: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8-9.8) in the G-CSF group and 6.8 months (95% CI, 6.2-7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6-18.1) for the G-CSF group and 10.6 months (95% CI, 7.9-13.3) for the non-G-CSF group (p = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12).
UNASSIGNED: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity.
■这次回顾展,多中心研究纳入接受卡铂联合依托泊苷和阿替珠单抗治疗的ES-SCLC患者,分为G-CSF和非G-CSF组。收集人口统计学和疾病相关数据。响应率,无进展生存期(PFS),总生存期(OS),并对毒性进行了分析。
■119名患者(平均年龄:63岁),总有效率(ORR)和疾病控制率(DCR)分别为72.3%和81.5%,分别。在G-CSF组中,ORR为76.4%,而非G-CSF组为60.0%(p=0.33),DCR分别为85.4%和70.0%,分别(p=0.46)。G-CSF组为8.3个月(95%CI,6.8-9.8),非G-CSF组为6.8个月(95%CI,6.2-7.5)(p=0.24)。G-CSF组为13.8个月(95%CI,9.6-18.1),非G-CSF组为10.6个月(95%CI,7.9-13.3)(p=0.47)。3级≥不良事件组间相似(49.4%vs.33.3%,分别,p=0.12)。
■G-CSF预防可以安全地用于接受卡铂联合依托泊苷和阿特珠单抗方案的ES-SCLC患者,而不会显着改变疗效或增加毒性。